Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Countries and organisations

Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.

Free access · No subscription for research tools or data exports

Explore registry geography and organisations

Reset

23 trials match this view; 22 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 1,254 across 23 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Recorded study-start years

201811
202133
202211
202333
202466
202533
202666

Current indexed registry status

Recruiting1010
Completed66
Active, not recruiting22
Not yet recruiting22
Unknown status22
Withdrawn11

Reported research conditions

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Countries with reported trial locations

Canada4141

Sponsors recorded in this index

Matching trial records

23 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

NCT07610369

Depression · Parkinson's Disease (PD)
Yale University

PHASE2

Recruiting

Registry updated 2026-09-28

40

ESTIMATED

2026-07-10
2030-07
2030-07
Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive Symptoms · Depression · Alzheimer Disease · Mild Cognitive Impairment
Johns Hopkins University

EARLY_PHASE1

Recruiting

Registry updated 2026-09-04

20

ESTIMATED

2021-03-24
2027-06-30
2027-09-30
Psilocybin and Affective Function in Chronic Lower Back Pain Depression

NCT06355414

Chronic Low-back Pain · Depression
Johns Hopkins University

PHASE1

Recruiting

Registry updated 2026-09-04

40

ESTIMATED

2024-04-22
2026-12-30
2026-12-30
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study

NCT04932434

Parkinson Disease · Depression · Anxiety
Joshua Woolley, MD, PhD

PHASE2

Completed

Registry updated 2026-09-03

12

ACTUAL

2021-08-15
2024-12-31
2024-12-31
Processing Intergenerational Trauma With Psilocybin-Assisted Therapy

NCT06899165

Psychological Stress · Depression · Anxiety
Rachel Yehuda

PHASE2

Recruiting

Registry updated 2026-08-13

100

ESTIMATED

2026-08-28
2029-05-31
2030-01-02
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

NCT06801041

Depression · Anxiety · Cancer
M.D. Anderson Cancer Center

PHASE2

Recruiting

Registry updated 2026-08-12

20

ESTIMATED

2025-05-23
2027-03-31
2029-03-31
An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)

NCT06512194

Depression
Charles Raison

PHASE2

Recruiting

Registry updated 2026-08-10

141

ESTIMATED

2025-05-13
2029-05
2029-05
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

NCT06455293

Parkinson Disease · Depression
Joshua Woolley, MD, PhD

PHASE2

Recruiting

Registry updated 2026-08-07

60

ESTIMATED

2024-08-19
2027-06
2028-06
A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression

NCT07336238

Anxiety · Depression · Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm
University of Washington

PHASE2

Active, not recruiting

Registry updated 2026-07-31

18

ESTIMATED

2026-05-19
2026-12-01
2027-05-01
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety

NCT06820723

Depression · Anxiety · Major Depressive Disorder
Ohio State University

PHASE2

Recruiting

Registry updated 2026-07-23

40

ESTIMATED

2026-08-01
2028-09
2028-11
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)

NCT06341426

Major Depressive Disorder · Depression · Treatment-Resistant Depression · Mood Disorders
University Health Network, Toronto

PHASE2

Active, not recruiting

Registry updated 2026-07-09

92

ESTIMATED

2024-02-05
2026-07-28
2026-12-28
A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression

NCT07582120

Depression
Washington University School of Medicine

PHASE2

Not yet recruiting

Registry updated 2026-05-20

50

ESTIMATED

2026-06
2031-06
2031-12
A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression

NCT07565909

Depression · Anxiety
University of Washington

PHASE2

Not yet recruiting

Registry updated 2026-05-04

72

ESTIMATED

2026-06
2027-12
2028-07
Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)

NCT05883540

Palliative Care · Pain · Anxiety · Depression · Demoralization · Psychological Distress · Quality of Life · Caregiver Burden · Fear of Death · Existential Distress
University Hospital, Basel, Switzerland

PHASE2

Recruiting

Registry updated 2026-04-29

60

ESTIMATED

2024-06-09
2027-09
2028-05
Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder

NCT06132178

Treatment Resistant Depression · MDD · Major Depressive Disorder · Recurrent Depression · Depression
University of Texas at Austin

PHASE2

Recruiting

Registry updated 2025-11-26

100

ESTIMATED

2025-01-10
2029-12-31
2030-12-31
Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study

NCT06372197

Depression
Matthew Hicks

NA

Completed

Registry updated 2025-06-05

20

ACTUAL

2024-08-01
2025-05-14
2025-05-14
A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout

NCT05163496

Burnout, Caregiver · Burnout, Professional · COVID-19 · Depression · Post Traumatic Stress Disorder · Moral Injury
University of Washington

PHASE3

Completed

Registry updated 2025-03-18

30

ACTUAL

2022-03-03
2023-12-30
2024-06-30
PAPR: Psilocybin-assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for Front-line Healthcare Provider COVID-19 Related Burnout

NCT05557643

Depression · Burnout, Professional
University of Utah

PHASE1

Completed

Registry updated 2024-11-12

24

ACTUAL

2023-01-02
2024-09-20
2024-09-20
A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder

NCT06444243

Alcohol Use Disorder · Alcohol Dependence · Depression · Anxiety
University of Sydney

PHASE2

Unknown status

Registry updated 2024-06-10

90

ESTIMATED

2024-09
2025-07
2025-12
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study

NCT04630964

Major Depressive Disorder · Depression
Section for Affective Disorders; Northern Stockholm Psychiatry

PHASE2

Completed

Registry updated 2024-04-19

35

ACTUAL

2021-01-01
2023-04-19
2024-04-18
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD).

NCT06141876

Post-traumatic Stress Disorder · Depression
Apex Labs Ltd.

PHASE2

Unknown status

Registry updated 2023-11-29

160

ESTIMATED

2023-12-15
2025-06-15
2025-06-15
Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)

NCT05594667

Depression · Major Depressive Disorder · Mild Depression · Moderate Depression · Depressive Disorder
Cybin Therapeutics Inc.

PHASE2

Withdrawn

Registry updated 2023-07-06

0

ACTUAL

2023-01-01
2023-03-14
2023-03-14
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

NCT02950467

Distress · Depression · Grief
Joshua Woolley

PHASE1

Completed

Registry updated 2021-01-07

30

ACTUAL

2018-01-05
2019-12-31
2019-12-31

Reported research facilities

Yale UniversityNew Haven, Connecticut, United States
Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States
Johns Hopkins University School of MedicineBaltimore, Maryland, United States
University of California, San FranciscoSan Francisco, California, United States
The Parsons Research Center for Psychedelic HealingNew York, New York, United States
The University of Texas M. D. Anderson Cancer CenterHouston, Texas, United States
Vail Health Behavioral HealthEdwards, Colorado, United States
Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States
The Ohio State University Department of PsychiatryColumbus, Ohio, United States
Toronto Western HospitalToronto, Ontario, Canada
Centre for Addiction and Mental Health (CAMH)Toronto, Ontario, Canada
Washington University School of MedicineSt Louis, Missouri, United States
University Hospital Basel, Division of Clinical Pharmacology and ToxicologyBasel, Switzerland
University Hospital Geneva, Palliative medicine departmentCollonge-Bellerive, Switzerland
Spital Uster AG, Division of Internal MedicineUster, Switzerland
University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative CareZurich, Switzerland
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600Austin, Texas, United States
National University of Natural MedicinePortland, Oregon, United States
University of WashingtonSeattle, Washington, United States
Huntsman Mental Health InstituteSalt Lake City, Utah, United States
Northern Stockholm Spychiatry ClinicStockholm, Sweden
Centre for Neurology Studies x UpstreamAbbotsford British Columbia, British Columbia, Canada

This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.